Table 1 Clinicopathologic features of high-grade serous carcinoma with and without STICHGSC: high-grade serous carcinoma; STIC: serous tubal intraepithelial carcinoma
From: IMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesis
HGSC w/ STIC (n = 48) | HGSC w/o STIC (n = 62) | P | |
|---|---|---|---|
No. (%) patients | |||
Age (y) mean ± SD | 57.2 ± 2.78 | 67.1 ± 2.32 | < 0.005 |
≦40 | 4 | 2 | |
41-50 | 9 | 6 | |
51-60 | 18 | 11 | |
61-70 | 10 | 22 | |
> 70 | 7 | 21 | |
STIC locations | |||
Left tube | 12 | ||
Right tube | 29 | ||
Bilateral tubes | 7 | ||
Invasive locations^ | |||
Left | 3 | 4 | |
Right | 5 | 6 | |
Bilateral | 37 | 52 | > 0.05 |
Cancer size (cm) mean ± SD | |||
Fallopian tube | 0.55 ± 0.21 | 2.66 ± 0.72 | < 0.05 |
Ovary | 3.42 ± 0.52 | 4.35 ± 0.64 | > 0.05 |
Stage | |||
I | 4 | 0 | < 0.05 |
II | 5 | 3 | > 0.05 |
III | 39 | 51 | > 0.05 |
IV | 0 | 8 | < 0.05 |
Breast cancer history | 8 | 7 | |
Family history | 12 | 12 | |
Prophylactic BSO | 5 | 0 | |